HRP20180262T1 - Monoklonska anti-gt468 protutijela za liječenje karcinoma - Google Patents
Monoklonska anti-gt468 protutijela za liječenje karcinoma Download PDFInfo
- Publication number
- HRP20180262T1 HRP20180262T1 HRP20180262TT HRP20180262T HRP20180262T1 HR P20180262 T1 HRP20180262 T1 HR P20180262T1 HR P20180262T T HRP20180262T T HR P20180262TT HR P20180262 T HRP20180262 T HR P20180262T HR P20180262 T1 HRP20180262 T1 HR P20180262T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- antibody
- conjugate
- antibodies
- cell
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 5
- 201000011510 cancer Diseases 0.000 title claims 3
- 210000004027 cell Anatomy 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 210000004408 hybridoma Anatomy 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010050017 Lung cancer metastatic Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025598 Malignant hydatidiform mole Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000008824 placental choriocarcinoma Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- -1 radioisotope Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Claims (8)
1. Protutijelo koje se bira iz skupine koju čini:
(i) protutijela koje je proizvedeno ili koje se može dobiti iz klona dpohranjenog pod pristupnim br. DSM ACC2944 (51-1A-1),
(ii) protutijela koje je kimerizirani ili humanizirani oblikprotutijela pod (i), i
(iii) protutijela koje sadrži dio koji se veže za antigen ili mjesto koje se veže za antigen protutijela pod (i),
pri čemu se navedeno protutijela veže za polipeptid koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 2 iz listinga sekvenci i inhibira proliferaciju stanica koje eksprimiraju navedeni polipeptid.
2. Hibridom odabran iz skupine koju čine:
(i) hibridoma koji proizvodi protutijela sukladno patentnom zahtjevu 1, i
(ii) hibridoma deponiranog pod pristupnim br. DSM ACC2944 (51-1A-1).
3. Konjugat koji sadrži protutijelo sukladno patentnom zahtjevu 1 povezano s terapijskim sredstvom, poželjno toksinom, radioizotopom, lijekom ili citotoksičnim sredstvom.
4. Farmaceutski pripravak koja sadrži protutijelo sukladno patentnom zahtjevu 1 i/ili konjugat sukladno patentnom zahtjevu 3, i farmaceutski prihvatljiv nosač.
5. Protutijelo sukladno patentnom zahtjevu 1 i/ili konjugat 3, naznačeno time da se koristi u postupku liječenja bolesti povezane s tumorom ili poremećajem povezanog s tumorom, naznačeno stanicama koje eksprimiraju polipeptid koji se sastoji od aminokiselinske sekvence prema SEQ ID NO: 2 iz listinga sekvenci i/ili karakteriziranje vezivanjem navedenog polipeptida s svojom površinom stanice subjekta.
6. Protutijelo ili konjugat za uporabu sukladno patentnom zahtjevu 5, pri čemu navedeni postupak liječenja je (i) postupak za inhibiranje rasta spomenute stanice, (ii) postupak za ubijanje spomenute stanice ili (iii) postupak za inhibiranje metastatskog širenja navedene stanice.
7. Protutijelo ili konjugat za uporabu sukladno patentnom zahtjevu 5 ili 6, pri čemu, bolest ili poremećaj je karcinom.
8. Protutijelo ili konjugat za uporabu sukladno patentnom zahtjevu 7, pri čemu, karacinom je odabran iz skupine koju čine karcinom dojke, karcinom pluća, karcinom želuca, karcinom jajnika, hepatocelularni karcinom, karcinom debelog crijeva, karcinom pankreasa, karcinom jednjaka, karcinom glave i vrata, karcinom bubrega, osobito karcinoma stanica bubrega, karcinom prostate, karcinom jetre, melanoma, sarkoma, mijeloma, neuroblastoma, placentalnog koriokarcinoma, karcinom grlića maternice, i tiroidnog karcinom, i njihovih metastatskih oblika, i metastatskog karcinoma pluća.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9745308P | 2008-09-16 | 2008-09-16 | |
| EP08016277A EP2166021A1 (en) | 2008-09-16 | 2008-09-16 | Monoclonal antibodies for treatment of cancer |
| PCT/EP2009/006704 WO2010031551A2 (en) | 2008-09-16 | 2009-09-16 | Monoclonal antibodies for treatment of cancer |
| EP09778564.6A EP2342234B1 (en) | 2008-09-16 | 2009-09-16 | Monoclonal anti-gt468 antibodies for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180262T1 true HRP20180262T1 (hr) | 2018-03-23 |
Family
ID=40589589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180262TT HRP20180262T1 (hr) | 2008-09-16 | 2018-02-13 | Monoklonska anti-gt468 protutijela za liječenje karcinoma |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8946388B2 (hr) |
| EP (3) | EP2166021A1 (hr) |
| JP (1) | JP2012502938A (hr) |
| KR (1) | KR101818741B1 (hr) |
| CN (3) | CN102164963B (hr) |
| AU (1) | AU2009294896B2 (hr) |
| BR (1) | BRPI0918178B8 (hr) |
| CA (1) | CA2732594C (hr) |
| CY (1) | CY1119956T1 (hr) |
| DK (1) | DK2342234T3 (hr) |
| ES (1) | ES2659718T3 (hr) |
| HK (1) | HK1253579A1 (hr) |
| HR (1) | HRP20180262T1 (hr) |
| HU (1) | HUE036477T2 (hr) |
| IL (2) | IL211010A (hr) |
| LT (1) | LT2342234T (hr) |
| MX (2) | MX357010B (hr) |
| NO (1) | NO2342234T3 (hr) |
| NZ (2) | NZ596490A (hr) |
| PL (1) | PL2342234T3 (hr) |
| PT (1) | PT2342234T (hr) |
| RS (1) | RS56937B1 (hr) |
| SI (1) | SI2342234T1 (hr) |
| TR (1) | TR201802090T4 (hr) |
| WO (1) | WO2010031551A2 (hr) |
| ZA (1) | ZA201100835B (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| EP1970384A1 (en) * | 2007-03-14 | 2008-09-17 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| ES2768224T3 (es) | 2007-08-17 | 2020-06-22 | Purdue Research Foundation | Conjugados ligando-enlazador de unión a PSMA y métodos para su uso |
| EP2166021A1 (en) | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| EP2371864A1 (en) * | 2010-03-23 | 2011-10-05 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| KR101989134B1 (ko) * | 2011-01-19 | 2019-06-13 | 칸타르기아 아베 | 항―ｉｌ１ｒａｐ 항체 및 그의 인간 치료 용도 |
| US20130236890A1 (en) * | 2012-03-08 | 2013-09-12 | HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH | Novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells |
| KR101471253B1 (ko) * | 2012-10-29 | 2014-12-10 | 인제대학교 산학협력단 | 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| CA2891476C (en) | 2012-11-15 | 2022-07-05 | Endocyte, Inc. | Drug delivery conjugates, and methods for treating diseases caused by psma expressing cells |
| SG11201602249RA (en) | 2013-10-18 | 2016-05-30 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| JP2017521998A (ja) * | 2014-05-12 | 2017-08-10 | ヌマブ アクチェンゲゼルシャフト | 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法 |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| ES2871252T3 (es) * | 2015-07-14 | 2021-10-28 | Medimmune Llc | Método para detectar células madre cancerosas |
| WO2017041001A2 (en) | 2015-09-04 | 2017-03-09 | The California Institute For Biomedical Research | Insulin immunoglobulin fusion proteins |
| CN108884158A (zh) * | 2015-12-01 | 2018-11-23 | 根马布有限公司 | 抗死亡受体抗体及其使用方法 |
| CN108738313B (zh) * | 2016-10-20 | 2022-12-30 | 天境生物科技(上海)有限公司 | 新的cd47单克隆抗体及其应用 |
| CN106632661A (zh) * | 2017-01-10 | 2017-05-10 | 天津东亚生物技术有限公司 | 利用hla‑g分子及其抗原片段制备预防肿瘤和病毒病的广谱疫苗及其应用 |
| CN108124445B (zh) * | 2017-03-15 | 2021-05-04 | 苏州银河生物医药有限公司 | Ctla4抗体、其药物组合物及其用途 |
| CN107556369A (zh) * | 2017-08-23 | 2018-01-09 | 天津国际生物医药联合研究院 | 一种抗原肽和用于检测肿瘤细胞的抗体制备方法及其应用 |
| CN109402064B (zh) * | 2018-11-05 | 2021-05-14 | 湖南省肿瘤医院 | 杂交瘤细胞株及其产生的单克隆抗体和应用 |
| KR102266418B1 (ko) * | 2019-07-30 | 2021-06-16 | 한국생명공학연구원 | 영여자 추출물을 유효성분으로 함유하는 전립선 질환의 예방 및 치료용 조성물 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| US5744585A (en) * | 1995-03-16 | 1998-04-28 | Medenica; Rajko D. | Human monoclonal antibody against lung carcinoma |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US20020065394A1 (en) * | 1998-03-18 | 2002-05-30 | Kenneth Jacobs | Secreted proteins and polynucleotides encoding them |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU2001284703B2 (en) | 2000-08-03 | 2007-03-22 | Therapeutic Human Polyclonals Inc. | Production of humanized antibodies in transgenic animals |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003075014A2 (en) | 2002-03-06 | 2003-09-12 | Oxford Glycosciences (Uk) Ltd | Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11 |
| NZ581541A (en) | 2002-10-17 | 2011-07-29 | Genmab As | Human monoclonal antibodies against CD20 |
| CA2513292C (en) * | 2003-01-17 | 2016-04-05 | The Chinese University Of Hong Kong | Circulating mrna as diagnostic markers for pregnancy-related disorders |
| US20050255114A1 (en) * | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
| CN1663603A (zh) | 2004-03-02 | 2005-09-07 | 北京大学 | 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用 |
| EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| EP1970384A1 (en) * | 2007-03-14 | 2008-09-17 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| EP2166021A1 (en) | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| CN107028969A (zh) * | 2009-02-20 | 2017-08-11 | 加尼梅德药物公司 | 用于癌症诊断和治疗的方法和组合物 |
| EP2221063A1 (en) * | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
-
2008
- 2008-09-16 EP EP08016277A patent/EP2166021A1/en not_active Withdrawn
-
2009
- 2009-09-16 TR TR2018/02090T patent/TR201802090T4/tr unknown
- 2009-09-16 NZ NZ596490A patent/NZ596490A/xx not_active IP Right Cessation
- 2009-09-16 EP EP17201134.8A patent/EP3312198A1/en not_active Withdrawn
- 2009-09-16 NZ NZ591004A patent/NZ591004A/en not_active IP Right Cessation
- 2009-09-16 LT LTEP09778564.6T patent/LT2342234T/lt unknown
- 2009-09-16 PL PL09778564T patent/PL2342234T3/pl unknown
- 2009-09-16 AU AU2009294896A patent/AU2009294896B2/en not_active Ceased
- 2009-09-16 JP JP2011527243A patent/JP2012502938A/ja active Pending
- 2009-09-16 ES ES09778564.6T patent/ES2659718T3/es active Active
- 2009-09-16 MX MX2015005367A patent/MX357010B/es unknown
- 2009-09-16 CN CN200980136101.9A patent/CN102164963B/zh not_active Expired - Fee Related
- 2009-09-16 CN CN201510373379.5A patent/CN105753988A/zh active Pending
- 2009-09-16 RS RS20180160A patent/RS56937B1/sr unknown
- 2009-09-16 BR BRPI0918178A patent/BRPI0918178B8/pt not_active IP Right Cessation
- 2009-09-16 KR KR1020117007149A patent/KR101818741B1/ko active IP Right Grant
- 2009-09-16 MX MX2011002856A patent/MX2011002856A/es active IP Right Grant
- 2009-09-16 NO NO09778564A patent/NO2342234T3/no unknown
- 2009-09-16 WO PCT/EP2009/006704 patent/WO2010031551A2/en active Application Filing
- 2009-09-16 DK DK09778564.6T patent/DK2342234T3/en active
- 2009-09-16 CA CA2732594A patent/CA2732594C/en active Active
- 2009-09-16 CN CN201410649373.1A patent/CN104628858B/zh not_active Expired - Fee Related
- 2009-09-16 US US13/119,027 patent/US8946388B2/en not_active Expired - Fee Related
- 2009-09-16 EP EP09778564.6A patent/EP2342234B1/en active Active
- 2009-09-16 PT PT97785646T patent/PT2342234T/pt unknown
- 2009-09-16 SI SI200931801T patent/SI2342234T1/en unknown
- 2009-09-16 HU HUE09778564A patent/HUE036477T2/hu unknown
-
2011
- 2011-02-01 ZA ZA2011/00835A patent/ZA201100835B/en unknown
- 2011-02-02 IL IL211010A patent/IL211010A/en not_active IP Right Cessation
-
2015
- 2015-10-22 IL IL242204A patent/IL242204B/en active IP Right Grant
-
2018
- 2018-02-13 HR HRP20180262TT patent/HRP20180262T1/hr unknown
- 2018-02-15 CY CY20181100189T patent/CY1119956T1/el unknown
- 2018-10-08 HK HK18112784.5A patent/HK1253579A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| JP7270522B2 (ja) | 増殖分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体 | |
| JP2012502938A5 (hr) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| HRP20200591T1 (hr) | Protutijela specifična za klaudin 6 (cldn6) | |
| TWI826828B (zh) | 抗her3抗體-藥物結合物及含有其之醫藥及醫藥組成物 | |
| JP2020510422A5 (hr) | ||
| HRP20180507T1 (hr) | Identifikacija antigena povezanih s tumorom za dijagnozu i terapiju | |
| JP6865585B2 (ja) | 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 | |
| JP2016187356A5 (hr) | ||
| JP2010535713A5 (hr) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| HRP20230078T1 (hr) | Sredstva za vezivanje vegf/dll4 i njihova uporaba | |
| RU2020124944A (ru) | Антитела против egfr и конъюгаты антитело-лекарственное средство | |
| JP2010110329A5 (hr) | ||
| JP2015529641A5 (hr) | ||
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| JP2010163438A5 (hr) | ||
| JP2014518615A5 (hr) | ||
| JP2010532169A5 (hr) | ||
| JP2015506912A5 (hr) | ||
| JP2014530017A5 (hr) | ||
| US11739154B2 (en) | AXL-specific antibodies and uses thereof |